Drug Combination Details
| General Information of the Combination (ID: C10976) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Decitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Myelodysplastic syndromes
[ICD-11: 2A36]
|
Phase 3 | [1] | ||
|
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Effect of decitabine in combination with arsenic trioxide on prolife-ration and apoptosis of human acute myeloid leukemia MV4-11 cells. | |||||
